<p><strong>Non-Hodgkin&#39;s Lymphoma</strong>&nbsp;(NHL): Rituximab is indicated for the treatment of patients with-</p>

<ul>
	<li>Relapsed or&nbsp;refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent</li>
	<li>Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line&nbsp;chemotherapy&nbsp;and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent&nbsp;maintenance therapy.</li>
	<li>Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line CVP chemotherapy</li>
	<li>Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other&nbsp;anthracycline-based chemotherapy regimens</li>
</ul>

<p><strong>Chronic Lymphocytic Leukemia</strong>&nbsp;(CLL): Rituximab is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive&nbsp;CLL.<br />
<br />
<strong>Rheumatoid Arthritis</strong>&nbsp;(RA): Rituximab in combination with methotrexate is indicated for the treatment of adult patients with moderately- to severely- active&nbsp;rheumatoid arthritis&nbsp;who have had an inadequate response to one or more&nbsp;TNF&nbsp;antagonist&nbsp;therapies.<br />
<br />
<strong>Granulomatos Is With Polyangiitis (GPA) (Wegener&#39;s Granulomatosis) and Microscopic Polyangiitis (MPA)</strong>: Rituximab, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener&#39;s Granulomatosis) andMicroscopic&nbsp;Polyangiitis (MPA).</p>